A drug for vertigo sometimes called Vastarel. Usually 0.020g per tablet.
Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, improves myocardial glucose utilization through inhibition of fatty acid oxidation.
It improves left ventricular function in diabetic patients with coronary artery disease.
It is described as the first cytoprotective anti-ischemic agent, acts by directly counteracting all the major metabolic disorders occurring within the ischemic cell. The actions of trimetazidine include limitation of intracellular acidosis, correction of disturbances of transmembrane ion exchanges, and prevention of excessive production of free radicals.